Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.biopha.2020.110529 http://scihub22266oqcxt.onion/10.1016/j.biopha.2020.110529 32736237!7386262!32736237     free     free     free Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 249.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Biomed+Pharmacother 2020 ; 130 (ä): 110529 Nephropedia Template TP {{tp|p=32736237|t=2020. Clinical efficacy of glucocorticoid on the treatment of patients with COVID-19 pneumonia: A single-center experience |pdf=|usr=}}{{32736237}} gab.com Text Clinical efficacy of glucocorticoid on the treatment of patients with COVID-19 pneumonia: A single-center experience JO: Biomed Pharmacother http://www.kidney.de/pget.php?&tw=1&pmid=32736237 #FOAvip The aim of the present study was to identify the clinical efficacy of glucocorticoid therapy on the treatment of patients with Coronavirus Disease 2019 (COVID-19) pneumonia. Clinical and laboratory parameters were collected from 308 patients with COVID-19 pneumonia from the fever clinic of Wuhan Pulmonary Hospital (Wuhan City, Hubei Province, China) between January 14, 2020 and February 9, 2020, of which 216 patients received low-dose (equivalent of methylprednisolone 0.75-1.5?mg/kg/d) glucocorticoid treatment. The effect of glucocorticoid on imaging progress, adverse events, nucleic acid results and the outcomes were investigated. Lymphocyte count and C-reactive protein (CRP) significantly differed between the glucocorticoid therapy and non-glucocorticoid therapy groups. Compared with the non-glucocorticoid therapy group, glucocorticoid therapy did not significantly influence the clinical course of COVID-19 pneumonia, including imaging progress and the time duration for negative transformation of nucleic acid. Glucocorticoid therapy did not significantly influence the outcomes nor the adverse events of COVID-19 pneumonia. For the treatment of COVID-19 pneumonia, systemic and in-depth investigation is needed to determine the timing and dosage of glucocorticoids needed to inhibit overwhelming inflammatory response and not the protective immune response to COVID-19 pneumonia. Twit Text FOAVip Clinical efficacy of glucocorticoid on the treatment of patients with COVID-19 pneumonia: A single-center experience ????Biomed Pharmacother http://www.kidney.de/pget.php?&tw=1&pmid=32736237 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32736237 #FOAvip English Wikipedia <ref>{{Cite pmid|32736237}}</ref> Clinical efficacy of glucocorticoid on the treatment of patients with COVID-19 pneumonia: A single-center experience #MMPMID32736237 Hu Y; Wang T; Hu Z; Wang X; Zhang Z; Li L; Peng P Biomed Pharmacother 2020[Oct]; 130 (ä): 110529 PMID32736237show ga The aim of the present study was to identify the clinical efficacy of glucocorticoid therapy on the treatment of patients with Coronavirus Disease 2019 (COVID-19) pneumonia. Clinical and laboratory parameters were collected from 308 patients with COVID-19 pneumonia from the fever clinic of Wuhan Pulmonary Hospital (Wuhan City, Hubei Province, China) between January 14, 2020 and February 9, 2020, of which 216 patients received low-dose (equivalent of methylprednisolone 0.75-1.5?mg/kg/d) glucocorticoid treatment. The effect of glucocorticoid on imaging progress, adverse events, nucleic acid results and the outcomes were investigated. Lymphocyte count and C-reactive protein (CRP) significantly differed between the glucocorticoid therapy and non-glucocorticoid therapy groups. Compared with the non-glucocorticoid therapy group, glucocorticoid therapy did not significantly influence the clinical course of COVID-19 pneumonia, including imaging progress and the time duration for negative transformation of nucleic acid. Glucocorticoid therapy did not significantly influence the outcomes nor the adverse events of COVID-19 pneumonia. For the treatment of COVID-19 pneumonia, systemic and in-depth investigation is needed to determine the timing and dosage of glucocorticoids needed to inhibit overwhelming inflammatory response and not the protective immune response to COVID-19 pneumonia. |*Betacoronavirus/isolation & purification[MESH] |*Pandemics[MESH] |Adolescent[MESH] |Adult[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |COVID-19 Testing[MESH] |Clinical Laboratory Techniques[MESH] |Coinfection/etiology[MESH] |Coronavirus Infections/diagnosis/diagnostic imaging/*drug therapy[MESH] |Female[MESH] |Humans[MESH] |Male[MESH] |Methylprednisolone/adverse effects/*therapeutic use[MESH] |Middle Aged[MESH] |Pharynx/virology[MESH] |Pneumonia, Viral/diagnosis/diagnostic imaging/*drug therapy[MESH] |Prednisolone/adverse effects/*therapeutic use[MESH] |RNA, Viral/analysis[MESH] |Retrospective Studies[MESH] |SARS-CoV-2[MESH] |Tomography, X-Ray Computed[MESH] |Treatment Outcome[MESH]Clinical efficacy of glucocorticoid on the treatment of patients with (epmc).pdf DeepDyve Pubget Overpricing